176 related articles for article (PubMed ID: 35778228)
1. ADAMTS-13/von Willebrand factor ratio: A prognostic biomarker for portal vein thrombosis in compensated cirrhosis. A prospective observational study.
Sacco M; Tardugno M; Lancellotti S; Ferretti A; Ponziani FR; Riccardi L; Zocco MA; De Magistris A; Santopaolo F; Pompili M; De Cristofaro R
Dig Liver Dis; 2022 Dec; 54(12):1672-1680. PubMed ID: 35778228
[TBL] [Abstract][Full Text] [Related]
2. Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study.
Lancellotti S; Basso M; Veca V; Sacco M; Riccardi L; Pompili M; De Cristofaro R
Intern Emerg Med; 2016 Oct; 11(7):959-67. PubMed ID: 27220954
[TBL] [Abstract][Full Text] [Related]
3. ADAMTS-13: A Prognostic Biomarker for Portal Vein Thrombosis in Japanese Patients with Liver Cirrhosis.
Suzuki J; Namisaki T; Takya H; Kaji K; Nishimura N; Shibamoto A; Asada S; Kubo T; Iwai S; Tomooka F; Takeda S; Koizumi A; Tanaka M; Matsuda T; Inoue T; Fujimoto Y; Tsuji Y; Fujinaga Y; Sato S; Kitagawa K; Kawaratani H; Akahane T; Mitoro A; Matsumoto M; Asada K; Yoshiji H
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473925
[TBL] [Abstract][Full Text] [Related]
4. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors.
Turon F; Driever EG; Baiges A; Cerda E; García-Criado Á; Gilabert R; Bru C; Berzigotti A; Nuñez I; Orts L; Reverter JC; Magaz M; Camprecios G; Olivas P; Betancourt-Sanchez F; Perez-Campuzano V; Blasi A; Seijo S; Reverter E; Bosch J; Borràs R; Hernandez-Gea V; Lisman T; Garcia-Pagan JC
J Hepatol; 2021 Dec; 75(6):1367-1376. PubMed ID: 34333101
[TBL] [Abstract][Full Text] [Related]
5. A new model of portal vein thrombosis in rats with cirrhosis induced by partial portal vein ligation plus carbon tetrachloride and intervened with rivaroxaban.
Guo Y; Dong S; Li M; Tao Y; Lv J; Liu C
BMC Gastroenterol; 2024 May; 24(1):161. PubMed ID: 38741060
[TBL] [Abstract][Full Text] [Related]
6. Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study.
Stine JG; Wang J; Shah PM; Argo CK; Intagliata N; Uflacker A; Caldwell SH; Northup PG
Liver Int; 2018 Jan; 38(1):94-101. PubMed ID: 28632958
[TBL] [Abstract][Full Text] [Related]
7. Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome.
Simbrunner B; Villesen IF; Scheiner B; Paternostro R; Schwabl P; Stättermayer AF; Marculescu R; Pinter M; Quehenberger P; Trauner M; Karsdal M; Lisman T; Reiberger T; Leeming DJ; Mandorfer M
Hepatol Int; 2023 Dec; 17(6):1532-1544. PubMed ID: 37605068
[TBL] [Abstract][Full Text] [Related]
8. The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease.
Scheiner B; Northup PG; Gruber AB; Semmler G; Leitner G; Quehenberger P; Thaler J; Ay C; Trauner M; Reiberger T; Lisman T; Mandorfer M
Liver Int; 2020 Jun; 40(6):1415-1426. PubMed ID: 32052552
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for portal venous thrombosis after splenectomy in patients with cirrhosis and portal hypertension.
Kinjo N; Kawanaka H; Akahoshi T; Tomikawa M; Yamashita N; Konishi K; Tanoue K; Shirabe K; Hashizume M; Maehara Y
Br J Surg; 2010 Jun; 97(6):910-6. PubMed ID: 20474001
[TBL] [Abstract][Full Text] [Related]
10. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis.
Han G; Qi X; He C; Yin Z; Wang J; Xia J; Yang Z; Bai M; Meng X; Niu J; Wu K; Fan D
J Hepatol; 2011 Jan; 54(1):78-88. PubMed ID: 20932597
[TBL] [Abstract][Full Text] [Related]
11. Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis.
La Mura V; Tripodi A; Tosetti G; Cavallaro F; Chantarangkul V; Colombo M; Primignani M
Liver Int; 2016 Sep; 36(9):1322-30. PubMed ID: 26854258
[TBL] [Abstract][Full Text] [Related]
12. Occlusive portal vein thrombosis as a new marker of decompensated cirrhosis.
Qi X; Bai M; Yang Z; Yuan S; Zhang C; Han G; Fan D
Med Hypotheses; 2011 Apr; 76(4):522-6. PubMed ID: 21216538
[TBL] [Abstract][Full Text] [Related]
13. Risk factors associated with portal vein thrombosis in liver cirrhosis: A case-control study.
Nadinskaia MY; Kodzoeva KB; Ulyanova KA; Volkova AS; Rogacheva SI; Dekhanov AS; Strelkova DA; Ivashkin VT
Ter Arkh; 2019 Mar; 91(2):73-81. PubMed ID: 31094175
[TBL] [Abstract][Full Text] [Related]
14. Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: A prospective study.
Noronha Ferreira C; Marinho RT; Cortez-Pinto H; Ferreira P; Dias MS; Vasconcelos M; Alexandrino P; Serejo F; Pedro AJ; Gonçalves A; Palma S; Leite I; Reis D; Damião F; Valente A; Xavier Brito L; Baldaia C; Fatela N; Ramalho F; Velosa J
Liver Int; 2019 Aug; 39(8):1459-1467. PubMed ID: 31021512
[TBL] [Abstract][Full Text] [Related]
15. [Portal vein flow rate used as a early predictor of portal vein thrombosis after periesophagastric devascularization].
Zhang Y; Wen TF; Chen ZY; Yan LN; Liang GL; Li G; Zhang XH; Ran S; Liao ZX
Zhonghua Wai Ke Za Zhi; 2009 Jun; 47(11):825-8. PubMed ID: 19961011
[TBL] [Abstract][Full Text] [Related]
16. Optimizing risk stratification in portal vein thrombosis after splenectomy and its primary prophylaxis with antithrombin III concentrates and danaparoid sodium in liver cirrhosis with portal hypertension.
Kawanaka H; Akahoshi T; Itoh S; Iguchi T; Harimoto N; Uchiyama H; Yoshizumi T; Shirabe K; Takenaka K; Maehara Y
J Am Coll Surg; 2014 Nov; 219(5):865-74. PubMed ID: 25256370
[TBL] [Abstract][Full Text] [Related]
17. De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system.
Abdel-Razik A; Mousa N; Elhelaly R; Tawfik A
Eur J Gastroenterol Hepatol; 2015 May; 27(5):585-92. PubMed ID: 25769098
[TBL] [Abstract][Full Text] [Related]
18. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
La Mura V; Reverter JC; Flores-Arroyo A; Raffa S; Reverter E; Seijo S; Abraldes JG; Bosch J; García-Pagán JC
Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
[TBL] [Abstract][Full Text] [Related]
19. [New targets for the prevention and treatment of cirrhotic portal vein thrombosis].
Wang YW; Ding HG
Zhonghua Gan Zang Bing Za Zhi; 2024 Jun; 32(6):484-488. PubMed ID: 38964888
[TBL] [Abstract][Full Text] [Related]
20. Serum ADAMTS-13 Levels as an Indicator of Portal Vein Thrombosis.
Mikuła T; Kozłowska J; Stańczak W; Sapuła M; Różyk A; Wiercińska-Drapało A
Gastroenterol Res Pract; 2018; 2018():3287491. PubMed ID: 29849584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
